{
  "slug": "multiple-sclerosis",
  "question": "What are the odds of developing multiple sclerosis?",
  "category": "health",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Multiple sclerosis sits in an odd cultural slot: the name is recognised, the broad picture (progressive, neurological, no cure) is roughly understood, but the actual lifetime odds are almost never the number readers reach for. Most adults, asked to guess, land somewhere between \"pretty rare\" and \"rare enough not to think about\". The two features of MS epidemiology that move the number the most — the sharp latitude gradient, and the 2022 finding that essentially every case is preceded by Epstein-Barr virus infection — are barely in the public conversation at all. MS is a fear that is recognised without being calibrated, and the personal odds attached to it drift far from the headline once you adjust for where you live, your sex, and whether you have ever had mono.\n",
    "rough_estimate": "Most adults guess lifetime MS risk well under 1 in 1,000",
    "kind": "intuition"
  },
  "native": {
    "display": "~2.9 million people living with MS worldwide (35.9 per 100,000)",
    "numerator": 1,
    "denominator": 800,
    "unit": "lifetime",
    "population": "global adults"
  },
  "normalized": {
    "lifetime_us_adult": 0.0013,
    "display": "1 in ~770 lifetime (global adult)",
    "log_value": -2.89,
    "assumptions": "Built from two complementary anchors. The Atlas of MS third edition (Walton et al., Mult Scler J, 2020) reports global point prevalence of 35.9 per 100,000 and a pooled incidence rate of 2.1 per 100,000 persons/year across 75 reporting countries. A naive lifetime cumulative incidence is (2.1e-5) × 60 adult years ≈ 1.26e-3, or roughly 1 in 800 global adults. The US population-based estimate from Wallin et al., Neurology 2019 — 309 to 363 per 100,000 point prevalence, equivalent to roughly 850,000 to 1 million Americans — implies a US lifetime incidence closer to 1 in 300 to 1 in 330 once competing mortality and the gap between point prevalence and cumulative incidence are handled. Using the global scope as the headline because US, Scotland, Scandinavia, and northern Canada each sit at ~3x the global average, while tropical and sub-Saharan regions sit well below it; a single global number is only defensible with a wide uncertainty band. Headline 0.0013 (~1 in 770), uncertainty 0.0005 to 0.005 to span the equatorial-to-high-latitude range.\n",
    "uncertainty": {
      "low": 0.0005,
      "high": 0.005
    },
    "scope": "global_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/33174475/",
      "title": "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition",
      "publisher": "Walton, King, Rechtman, Kaye, Leray, Marrie, et al. / Multiple Sclerosis Journal (MS International Federation)",
      "source_type": "peer_reviewed",
      "statistic": "Global MS prevalence 35.9 per 100,000 (2.8 million people); pooled incidence 2.1 per 100,000 persons/year across 75 countries; mean diagnosis age 32 years; female:male prevalence ratio roughly 2:1 globally",
      "excerpt": "\"A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males.\"\n",
      "source_date": "2020-12-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413180705/https://pubmed.ncbi.nlm.nih.gov/33174475/",
      "calculation_notes": "The Atlas is the only global dataset that reports prevalence, incidence, and sex ratio on a comparable basis across WHO regions. Global lifetime adult incidence ≈ incidence rate × adult years exposed = 2.1e-5 × 60 ≈ 0.00126, which is the normalized headline rounded to 0.0013. Regional prevalence ranges from 4.79 per 100,000 (Western Pacific) to 142.81 per 100,000 (Europe) — roughly a 30-fold spread that the regional_breakdown block below captures. The 2020 figure has since been updated to ~2.9 million in the 2023 Atlas refresh, but the core 35.9/100,000 rate and the 2.1/100,000/year incidence are still the canonical peer-reviewed anchors.\n",
      "independence_note": "Walton 2020 is the upstream source for nearly every institutional MS prevalence citation (WHO, National MS Society, MSIF member orgs); treat as partially dependent with any Atlas-derived secondary source.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6442006/",
      "title": "The prevalence of MS in the United States: A population-based estimate using health claims data",
      "publisher": "Wallin, Culpepper, Campbell, Nelson, Langer-Gould, Marrie, et al. / Neurology (American Academy of Neurology)",
      "source_type": "peer_reviewed",
      "statistic": "US MS prevalence 309.2 per 100,000 (95% CI 308.1-310.1) in 2010, representing 727,344 cases; 2017 projection 337.9 to 362.6 per 100,000 (~850,000 to 914,000 Americans); female:male ratio 2.8; persistent north-south gradient",
      "excerpt": "\"309.2 per 100,000 (95% CI 308.1–310.1), representing 727,344 cases [...] 450.1 per 100,000 (95% CI 448.1–451.6) for women and 159.7 (95% CI 158.7–160.6) for men (female:male ratio 2.8) [...] the prevalence in the northern Census regions of the US (Northeast and Midwest) was statistically significantly higher than in the southern Census region [...] 337.9 per 100,000 population (n = 851,749 persons with MS) to 362.6 per 100,000 population (n = 913,925 persons with MS).\"\n",
      "source_date": "2019-02-15",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260420044334/https://pmc.ncbi.nlm.nih.gov/articles/PMC6442006/",
      "calculation_notes": "Wallin 2019 is the methodologically strongest US prevalence estimate — a health-claims-based analysis that roughly doubled the previous conventional figure of ~400,000 Americans with MS to ~900,000+, much of the gap reflecting undercount in earlier methods rather than any real epidemic. The female:male prevalence ratio of 2.8 is the direct source for the ~3:1 sex ratio used in the personal_factor_multipliers block. US lifetime adult incidence implied: ~360 per 100,000 point prevalence with average MS duration ~25-30 years → annual incidence ~12 to 14 per 100,000 → 60-year cumulative ~0.0075, but this overstates lifetime risk because age-specific incidence peaks at 20-40 and is much lower outside that window. The ACS-style cohort-based US lifetime risk figure most commonly cited is ~1 in 300 to 1 in 330, consistent with these numbers. The north-south gradient inside the US is the smaller-scale version of the global latitude effect.\n",
      "independence_note": "Wallin 2019 and Walton 2020 are methodologically independent (claims data in one country vs international epidemiologic survey) and rely on different upstream datasets, which is why they are paired here.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/35025605/",
      "title": "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis",
      "publisher": "Bjornevik, Cortese, Healy, Kuhle, Mina, Leng, Elledge, Niebuhr, Scher, Munger, Ascherio / Science",
      "source_type": "primary_study",
      "statistic": "Hazard ratio for MS after EBV infection = 32.4 (95% CI 4.3-245.3); cohort of >10 million US military personnel, 955 MS cases; not elevated after other viral infections (e.g. cytomegalovirus); serum neurofilament light increased only after EBV seroconversion",
      "excerpt": "\"Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS.\"\n",
      "source_date": "2022-01-21",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413180822/https://pubmed.ncbi.nlm.nih.gov/35025605/",
      "calculation_notes": "Bjornevik et al. is the primary anchor for the \"EBV is likely a necessary cause of MS\" framing. The study followed >10 million young adults in the US military over 20 years; of the ~5% who were EBV- negative at baseline, only one of 801 who eventually developed MS remained EBV-negative, and the 32-fold hazard ratio is the direct source for the multiplier value in the personal_factor_multipliers block. The implication for population risk is not a 32x increase in absolute lifetime odds (EBV seroprevalence is ~95% in adults anyway), but rather that the conditional odds given EBV-negative status are near zero. This reframes MS as an infectious-disease sequel rather than a mystery autoimmune disease.\n",
      "independence_note": "Bjornevik et al. is a primary longitudinal cohort study built on US Department of Defense serum repository samples and DoD MS case ascertainment. Fully independent of the Walton (Atlas of MS) and Wallin (US claims) prevalence pipelines — addresses etiology rather than incidence/prevalence.\n"
    },
    {
      "url": "https://www.atlasofms.org/",
      "title": "Atlas of MS: Number of people with MS",
      "publisher": "MS International Federation",
      "source_type": "reputable_reference",
      "statistic": "Global MS population grew from 2.3 million in 2013 to 2.8 million in 2020 to 2.9 million in 2023",
      "excerpt": "\"The number of people with MS across the globe has increased from 2.3 million in 2013 to 2.8 million in 2020 and 2.9 in 2023.\"\n",
      "source_date": "2023-10-01",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20200907082035/http://www.atlasofms.org/",
      "calculation_notes": "Used as the continuously updated headline anchor for the \"~2.9 million people living with MS globally\" statement. The 2.9M figure is the most recent refresh of the same Atlas methodology that produced the peer- reviewed Walton 2020 paper, so the per-100,000 rate and incidence rate in the primary source remain the quantitative basis; the 2.9M update is used only for the headline count.\n",
      "independence_note": "Directly downstream from the Walton 2020 peer-reviewed source above; not an independent estimate, just a more recent snapshot of the same data pipeline.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Lifetime Alzheimer's / dementia mortality (global adult)",
      "lifetime_us_adult": 0.12
    },
    {
      "label": "Lifetime lung cancer incidence (US adult)",
      "lifetime_us_adult": 0.062
    },
    {
      "label": "Death in a car crash (lifetime, US)",
      "lifetime_us_adult": 0.0108
    },
    {
      "label": "Death by lightning strike (lifetime, US)",
      "lifetime_us_adult": 0.00000354
    },
    {
      "label": "Death in a plane crash (lifetime, US adult, regular flyer)",
      "lifetime_us_adult": 0.000017
    }
  ],
  "regional_breakdown": [
    {
      "region": "Global average",
      "probability": 0.0013,
      "notes": "Walton 2020 global incidence of 2.1 per 100,000 persons/year compounded across adult life"
    },
    {
      "region": "US adult",
      "probability": 0.003,
      "notes": "Wallin 2019 US point prevalence ~360 per 100,000 implies lifetime incidence roughly 1 in 300 to 1 in 330; a north-south gradient inside the US persists"
    },
    {
      "region": "Scotland, northern Canada, Scandinavia",
      "probability": 0.005,
      "notes": "Highest-prevalence regions globally; consistent with the latitude gradient — MS prevalence scales roughly with distance from the equator"
    },
    {
      "region": "Equatorial and tropical regions",
      "probability": 0.0002,
      "notes": "Western Pacific region reports ~4.8 per 100,000 prevalence in the Atlas of MS — roughly an order of magnitude below the global average"
    },
    {
      "region": "Women (global)",
      "probability": 0.0045,
      "notes": "Atlas of MS female:male ratio ~2:1 globally; Wallin 2019 US ratio 2.8; women's lifetime incidence sits at roughly 3x the male figure in most cohorts"
    },
    {
      "region": "Men (global)",
      "probability": 0.0015,
      "notes": "Men's lower lifetime incidence is a real biological gap, not a longevity artefact — MS onset peaks decades before competing mortality matters"
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Epstein-Barr virus seropositive vs seronegative",
      "multiplier": 32,
      "notes": "Bjornevik et al. Science 2022 hazard ratio (95% CI 4.3-245.3) in the US military cohort; EBV is likely a necessary though not sufficient cause of MS. Population-level effect is small because EBV seroprevalence in adults is already ~95%"
    },
    {
      "factor": "female",
      "multiplier": 3,
      "notes": "Wallin 2019 US female:male prevalence ratio 2.8; Atlas of MS reports global ratio roughly 2:1. Gap is real and not fully explained by longer reporting horizons"
    },
    {
      "factor": "first-degree relative with MS",
      "multiplier": 7,
      "notes": "Sibling and parent concordance studies give relative risks around 7x vs the general population; twin concordance pushes higher for monozygotic pairs"
    },
    {
      "factor": "HLA-DRB1*15:01 allele",
      "multiplier": 3,
      "notes": "Strongest common genetic risk factor for MS; approximately 3x odds ratio per copy in European-ancestry cohorts"
    },
    {
      "factor": "low vitamin D / low sun exposure",
      "multiplier": 1.4,
      "notes": "Part of the mechanism behind the latitude gradient; observational studies consistently show ~30-50% higher MS risk in lowest-vitamin-D quartiles"
    },
    {
      "factor": "smoking",
      "multiplier": 1.5,
      "notes": "Meta-analyses of smoking and MS onset give relative risks of roughly 1.5x; smoking also accelerates progression once MS is diagnosed"
    }
  ],
  "short_label": "MS",
  "myth_framing": "underrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "recurring",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "The global headline number compresses a very large spread. MS prevalence correlates sharply with latitude — Europe and the Americas sit roughly 3 to 5x above the global mean and the Western Pacific / equatorial regions sit an order of magnitude below — so the single 1-in-770 figure is best read as a midpoint, not a universal baseline. The perceived-vs-actual gap for this fear is not primarily about the headline probability; it is about two reframings that have only recently settled into the epidemiology literature. First, Bjornevik et al. 2022 implies that prior EBV infection is effectively a necessary condition for MS, which changes the disease's status from \"unexplained autoimmune\" to \"late sequel of a common herpesvirus infection\". Second, modern disease-modifying therapies have dramatically narrowed the life-expectancy gap between MS patients and the general population — MS in 2026 is not the same disease it was in 1986, even if it is still not curable. This entry is incidence-based, not mortality-based, for that reason: framing MS as \"odds of dying from MS\" would misrepresent both the disease course and the patient experience under current treatment.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.625,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single pale compass needle pointing north on a muted grey-blue background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/multiple-sclerosis"
}